Five years of experience with hydroxyurea in children and young adults with sickle cell disease. - Wikidata - awgldk - TriplyDB

Five years of experience with hydroxyurea in children and young adults with sickle cell disease.

Five years of experience with hydroxyurea in children and young adults with sickle cell disease.

http://www.wikidata.org/entity/Q43615402

about

Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease Patient-specific blood rheology in sickle-cell anaemia.Patient-specific modeling of individual sickle cell behavior under transient hypoxia.Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).Hydroxyurea treatment of children with hemoglobin SC disease.Urine concentrating ability in infants with sickle cell disease: baseline data from the phase III trial of hydroxyurea (BABY HUG).Effective control of sickle cell disease with hydroxyurea therapy.How I use hydroxyurea to treat young patients with sickle cell anemia.Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization.National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008.Management of sickle cell disease: a review for physician education in Nigeria (sub-saharan Africa).The role of hydroxyurea in sickle cell disease.Therapeutic challenges in childhood sickle cell disease. Part 1: current and future treatment options.Therapeutic challenges in childhood sickle cell disease. Part 2: a problem-orientated approach.Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)."Sickle Cell Disease in the Emergency Department: Atypical Complications and Management"Pharmacotherapy in sickle cell disease--state of the art and future prospects Survival and mortality among users and non-users of hydroxyurea with sickle cell disease.Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?Myocardial ischaemia in children with sickle cell disease Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia Management of sickle cell disease in primary care.Decision analysis of treatment strategies in children with severe sickle cell disease.Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study Gum Arabic as fetal hemoglobin inducing agent in sickle cell anemia; in vivo study.No improvement in suboptimal vitamin A status with a randomized, double-blind, placebo-controlled trial of vitamin A supplementation in children with sickle cell disease.Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.The genomics of new drugs in sickle cell disease.Hydroxyurea for children with sickle cell disease The prevention and management of stroke in sickle cell anaemia.Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease.Sickle cell disease in North Europe.Barriers to hematopoietic cell transplantation clinical trial participation of african american and black youth with sickle cell disease and their parents.Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation.Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities.Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.Role of hydroxycarbamide in prevention of complications in patients with sickle cell disease.The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design.Hydroxycarbamine: from an Old Drug Used in Malignant Hemopathies to a Current Standard in Sickle Cell Disease.Current strategies for the management of children with sickle cell disease.

P2860

Q24610970-FFF39C04-7459-406B-882E-B6EF73DB2EC9 Q30691183-3E17810C-E3AC-4603-ADAF-DF421835C248 Q30843061-94A1D5C3-B8F5-41F3-B90A-6782EF137D62 Q33345042-A8235D18-6A73-4BC6-A3B0-55F44ADC2649 Q33403128-554D995C-EBC4-491B-B326-FDE42A6A2857 Q33484805-4B7C6385-AFA7-48E7-B967-8D9AEAA7416E Q33913096-334D6372-61C7-4BCC-82F8-1E252DD1C460 Q33985120-910561DA-14A3-42DC-B00A-2D32FFB90034 Q34026647-7E17CCE7-ED16-4B79-92A2-B29633D94F50 Q34253814-25591CFA-31B9-4A66-97D3-EDC3C1FED6C3 Q35034032-0B7E6D5D-E309-451C-875C-7ED9B881A4A9 Q35050928-312453CE-9EAE-4913-AA2B-07F2F55CFA17 Q35076604-0D0CEC62-76BB-41BA-B500-6F66C463993D Q35076607-EE2498AE-2C43-4BB6-8D3C-465E0FE94267 Q35097294-AF379D80-2D97-435F-A9FC-6DAA31A1E99A Q35212165-F3B6E33C-4153-4B4B-94BF-92273C52A52D Q35220342-D5B165E6-8B45-4845-B14D-A2659CFD6FD1 Q35222814-06910DF6-1111-4D89-82FF-EF1D29ED90C4 Q35234959-06348731-001E-4527-AC86-3353DD185167 Q35278821-6CCDF9EF-30D6-4119-8CC2-C9710FDC5DD1 Q35353627-D456100C-25BF-4931-A2EA-36D05D3BF578 Q35611782-D866CA90-149A-432A-8842-67A293B32E6E Q35800106-AC893D74-ACFC-4113-B202-0522E938EAC0 Q35848253-2F9645A1-79AB-4CE7-A9BD-7D7AC681D741 Q35882386-34289590-FB6D-4B3C-92D2-C74D82E9EB1B Q36231661-EE2269B6-9710-460D-AEED-EF38D00C151C Q36243884-E35D3AD1-EAD0-4F58-8C00-CCE4CB82B12D Q36596719-9311F6F8-0AAB-4DAE-AD1C-A81C99D9C5AC Q36612962-05BDA09C-E92C-41BF-A459-50A20DF26E7F Q36627220-249BA774-C24C-4DC1-AB93-58F75DB299E6 Q36742702-6D3B4296-11D9-49A2-9C9F-2AA233F12058 Q36762093-0F34FB0E-8788-4F4B-BD35-B687984ED20A Q36860550-A06FB33A-D2A3-42BF-AB4F-A8AB2F276A8F Q37008748-15E1282C-3E14-407B-B03F-8B7B31812199 Q37223344-E2A55B59-6E2A-4E24-9CF6-3D3A4E314427 Q37258852-51CA51BB-4CE9-436B-86F7-B5EBD2E09B58 Q37367662-B6C294A7-3E2A-437D-85A3-73A0F0FA4641 Q37480741-B7A81906-6A28-4224-8836-89FC311D86F5 Q37677221-B3B777E7-4F1B-4B6E-B0F7-C73A7A084DFD Q37810082-3931434B-7941-4F94-A604-89C3B5CE04C8

P2860

Five years of experience with hydroxyurea in children and young adults with sickle cell disease.

http://www.wikidata.org/entity/Q43615402

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Five years of experience with ...... ults with sickle cell disease.

@en

Five years of experience with ...... ults with sickle cell disease.

@nl

type

label

Five years of experience with ...... ults with sickle cell disease.

@en

Five years of experience with ...... ults with sickle cell disease.

@nl

prefLabel

Five years of experience with ...... ults with sickle cell disease.

@en

Five years of experience with ...... ults with sickle cell disease.

@nl

P1433

Q43615402-9850F48F-6216-4606-8F0A-0965A71E3560

P1476

Q43615402-9EF7C4BD-4ED2-4894-85CE-173A685837F5

P2093

Q43615402-2A424C67-E6EB-47AE-A7DB-B245563C6540

Q43615402-568D20FB-C5E0-4AC7-8495-C151323F5F85

Q43615402-609B0979-8F85-44F8-B6CE-DD01EEC06730

Q43615402-AD74333E-88C4-4675-9948-F2FEC7AD106F

Q43615402-C2F764E2-57BA-4D0A-AE42-0D4899488761

Q43615402-C3EA0148-7F1D-43AB-B8BD-0437A94139A0

Q43615402-C4375E74-1FE8-400E-8837-60F8201DA82E

Q43615402-D0281BB2-4440-43E9-B80A-105423BA922D

Q43615402-D7146C1E-44CF-4B00-A48F-7E6196264EF1

Q43615402-E0E4CA37-5A4D-4AFF-8A67-5A3FD2864740

P304

Q43615402-7CCE60CC-F100-45E5-8D2D-4FB41A0EEE77

P31

Q43615402-C067ABB0-E048-428E-85ED-144CB2D8DB5B

P356

Q43615402-EBA17931-A9C3-46DE-9C07-0D3368FDFB5F

P407

Q43615402-19C2047C-6488-4121-BE02-13FAE150DE00

P433

Q43615402-AA82B3D5-495D-4B89-B8C9-FC7986645FCE

P478

Q43615402-AF8BCD99-8B89-453D-9033-B3396D7B9C59

P577

Q43615402-BF39A7BF-8E13-4E46-BF7A-C49FFD2A0F58

P5875

Q43615402-0FE3EABB-A88A-45B2-A2EF-9359D1193B83

P698

Q43615402-1D457C1C-F830-49E9-B1D7-A8886BBE89AA

P921

Q43615402-071088DB-F8F3-43E0-9F36-0446995E66A5

P356

BLOOD.V97.11.3628

P1433

P1476

Five years of experience with ...... ults with sickle cell disease.

@en

P2093

Corazza F

http://www.w3.org/2001/XMLSchema#string

Devalck C

http://www.w3.org/2001/XMLSchema#string

Dresse MF

http://www.w3.org/2001/XMLSchema#string

Feremans W

http://www.w3.org/2001/XMLSchema#string

Ferster A

http://www.w3.org/2001/XMLSchema#string

Fondu P

http://www.w3.org/2001/XMLSchema#string

Hunninck K

http://www.w3.org/2001/XMLSchema#string

Philippet P

http://www.w3.org/2001/XMLSchema#string

Sariban E

http://www.w3.org/2001/XMLSchema#string

Sturbois G

http://www.w3.org/2001/XMLSchema#string

P304

3628-3632

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD.V97.11.3628

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P577

2001-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11967907

http://www.w3.org/2001/XMLSchema#string

P698

11369660

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease